SMT Launches Hydra TAVI System in Hungary, Expands Global Footprint with Positive Early Results
25.11.2024 - 05:56:07
(Sahajanand Medical Technologies), a global leader in innovative vascular solutions, announces the launch of its Hydra Transcatheter Aortic Valve Implantation (TAVI) system in Hungary, debuting with promising results at Szegedi Tudományegyetem Szent-György Albert Klinikai Központ. Under the skilled leadership of Dr. Ruzsa Zoltán and Dr. Szücsborús Tamás, the Hydra TAVI system has demonstrated positive initial outcomes, marking a significant milestone in advancing minimally invasive treatments for aortic stenosis.
The Hydra TAVI system is crafted to address critical clinical needs by offering precise implantation and simplified coronary access, enabling safe and efficient procedures for aortic valve replacement. With an adaptable and robust design, Hydra offers healthcare professionals an advanced solution designed to enhance patient outcomes in cardiac care.
“With the successful launch of Hydra in Hungary, SMT has further expanded it global TAVI program. We are thrilled with the positive feedback received and it inspires us to keep on innovating and creating a positive impact on patient healthcare,” said Gaurav Goel, President of SMT’s Hydra business.
With Hydra TAVI now available in 20+ countries, SMT’s global expansion strategy reflects its commitment to making high-quality cardiovascular solutions accessible worldwide. This availability emphasizes SMT’s mission to enhance patient outcomes by providing advanced, minimally invasive options for cardiac care globally.
“Hydra’s precision in implantation is essential to patient safety and treatment efficacy,” commented Dr. Zoltán Ruzsa, MD, PhD. “Our initial experience with Hydra has been very promising, supporting our goal to deliver advanced, effective care.”
Dr. Tamás Szücsborus Tamás added, “Hydra TAVI aligns perfectly with our objectives to provide patients with innovative and accessible solutions for aortic valve disease.”
About SMT (Sahajanand Medical Technologies)
SMT is a global leader in cardiovascular medical devices, specializing in drug-eluting stents and structural heart disease solutions. Operating in over 80 countries, SMT is dedicated to advancing patient care through innovative medical technologies and clinical excellence, as demonstrated by the Multivessel TALENT trial. SMT has achieved recognitions from the Ministry of Health Sciences & Technologies for its tremendous contributions in the field of coronary healthcare. SMT also pioneered the introduction of biodegradable polymers in the cardiovascular segment.
https://smtpl.com/
About Hydra
Hydra is re-sheathable, re-positionable and retrievable self-expanding transcatheter aortic valve ensuring patient safety and good results during deployment. It has advanced features like markers on the frame for accurate guidance while deploying the frame. Hydra has a supra-annular design which helps in larger aortic valve area and best-in-class hemodynamic performance post procedure.
Hydra has less metal in the outflow portion which in turn helps in flexibility and ease of delivery of the frame reducing the chance of trauma to the aortic arch and sealing skirt mitigates paravalvular leak. Non-flared inflow part of stent frame reduces interference with the conduction system. Large open cells facilitate easy future coronary access.
The Hydra TAVI system is crafted to address critical clinical needs by offering precise implantation and simplified coronary access, enabling safe and efficient procedures for aortic valve replacement. With an adaptable and robust design, Hydra offers healthcare professionals an advanced solution designed to enhance patient outcomes in cardiac care.
“With the successful launch of Hydra in Hungary, SMT has further expanded it global TAVI program. We are thrilled with the positive feedback received and it inspires us to keep on innovating and creating a positive impact on patient healthcare,” said Gaurav Goel, President of SMT’s Hydra business.
With Hydra TAVI now available in 20+ countries, SMT’s global expansion strategy reflects its commitment to making high-quality cardiovascular solutions accessible worldwide. This availability emphasizes SMT’s mission to enhance patient outcomes by providing advanced, minimally invasive options for cardiac care globally.
“Hydra’s precision in implantation is essential to patient safety and treatment efficacy,” commented Dr. Zoltán Ruzsa, MD, PhD. “Our initial experience with Hydra has been very promising, supporting our goal to deliver advanced, effective care.”
Dr. Tamás Szücsborus Tamás added, “Hydra TAVI aligns perfectly with our objectives to provide patients with innovative and accessible solutions for aortic valve disease.”
About SMT (Sahajanand Medical Technologies)
SMT is a global leader in cardiovascular medical devices, specializing in drug-eluting stents and structural heart disease solutions. Operating in over 80 countries, SMT is dedicated to advancing patient care through innovative medical technologies and clinical excellence, as demonstrated by the Multivessel TALENT trial. SMT has achieved recognitions from the Ministry of Health Sciences & Technologies for its tremendous contributions in the field of coronary healthcare. SMT also pioneered the introduction of biodegradable polymers in the cardiovascular segment.
https://smtpl.com/
About Hydra
Hydra is re-sheathable, re-positionable and retrievable self-expanding transcatheter aortic valve ensuring patient safety and good results during deployment. It has advanced features like markers on the frame for accurate guidance while deploying the frame. Hydra has a supra-annular design which helps in larger aortic valve area and best-in-class hemodynamic performance post procedure.
Hydra has less metal in the outflow portion which in turn helps in flexibility and ease of delivery of the frame reducing the chance of trauma to the aortic arch and sealing skirt mitigates paravalvular leak. Non-flared inflow part of stent frame reduces interference with the conduction system. Large open cells facilitate easy future coronary access.
